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The small/short heterodimer partner (SHP, NR0B2) is a nuclear receptor corepressor lacking
a DNA binding domain. SHP is induced by bile acid-activated farnesoid X receptor (FXR)
resulting in CYP7A1 gene suppression. In contrast, Pregnane X receptor (PXR) activation
by its ligands was recently suggested to inhibit SHP gene transactivation to maximize the
induction of PXR target genes. However, there are also conﬂicting reports in literature
whether PXR or rodent Pxr activation down-regulates SHP/Shp expression. Moreover, the
PXR-mediated regulation of the SHP gene has been studied only at the SHP mRNA and
transactivation (gene reporter assay) levels. In this study,we studied the effect of rifampicin,
a prototype PXR ligand, on SHP mRNA, and protein expression in three primary human
hepatocyte cultures. We found that SHP mRNA is not systematically down-regulated in
hepatocyte in culture after 24 h treatment with rifampicin. Consistently, we did not observe
down-regulation of SHP protein in primary human hepatocytes after 24 and 48 h of incu-
bation with rifampicin.We can conclude that although we observed slight down-regulation
of SHP mRNA and protein in several hepatocyte preparations, the phenomenon is unlikely
critical for PXR-mediated induction of its target genes.
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INTRODUCTION
The small/short heterodimer partner (SHP, NR0B2) is a mem-
ber of the nuclear receptor family (nuclear receptor subfam-
ily 0, group B, member 2) with the highest expression in the
liver. SHP is an unusual nuclear receptor since it lacks a con-
ventional DNA binding domain and the main function of SHP
appears to be repression of other nuclear receptors via com-
petition with their coactivators (Seol et al., 1996; Bavner et al.,
2005) http://en.wikipedia.org/wiki/Small_heterodimer_partner -
cite_note-pmid16275121-2.
Recently, SHP has been shown to be involved in the con-
trol of bile acid biosynthesis. The ﬁrst and rate limiting step
of bile acid biosynthesis is catalyzed by cytochrome P450 7α
(CYP7α; 7α-hydroxylase) in the liver. Two different labora-
tories have concomitantly found that chenodeoxycholic acid
(CDCA) via farnesoid X receptor (FXR) induces the expres-
sion of SHP, which then binds to and inhibits LRH-1, an
orphan receptor that regulates CYP7α expression (Goodwin et al.,
2000; Lu et al., 2000). SHP is thus a negative nuclear recep-
tor that is induced by bile acid-activated FXR and inhibits the
CYP7A1 gene expression, a key regulatory gene in bile acid
synthesis.
Pregnane X receptor (PXR, NR1I2) is a ligand-activated tran-
scription factor, which is activated by a broad range of lipophilic
compounds including a myriad of drugs, by some synthetic and
endogenous steroids, certain bile acids, and natural products. PXR
is referred to as a “master regulator” or “xenosensor” for the
metabolism and clearance of diverse endogenous and exogenous
compounds (Tirona and Kim, 2005; Pavek and Dvorak, 2008;
Biswas et al., 2009).
CYP3A4 enzyme is the most important enzyme of
the cytochrome P450 superfamily, which metabolizes almost
50% of commonly used drugs (Li et al., 1995; Martinez-
Jimenez et al., 2007; Pavek and Dvorak, 2008). Impor-
tantly, CYP3A4 is the most important and well-studied tar-
get gene of PXR (Goodwin et al., 1999; Martinez-Jimenez
et al., 2007; Pavek et al., 2010). Consistently, CYP3A4 is
highly expressed in key sites of drug disposition such as
in the liver and small intestine. In addition, PXR regulates
the expression of several other important drug/xenobiotic-
metabolizing enzymes such as CYP2C9, CYP2B6, CYP2C19,
CYP3A5, UGT1A1, and SULT2A1 as well as drug transporters
such as MDR1 (P-glycoprotein) and MRP2 (Pavek and Dvorak,
2008).
Small/short heterodimer partner has been reported to sup-
press transcriptional activity of PXR in various cell models in vitro
(Wang et al., 2002; Ourlin et al., 2003; Li and Chiang, 2005) and
in Shp wild-type mice, but not in Shp null mice in vivo (Wang
et al., 2002). In cell-based transient transfection reporter assays,
the overexpression of SHP produced a dose-dependent inhibition
of bothmouse Pxr and human PXR transcriptional activities. This
inhibition was escaped by the overexpression of steroid receptor
coactivator-1 (SRC1,nuclear receptor coactivator-1,NCOA1) sug-
gesting competition of the coactivator with SHP corepressor on
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PXR (Ourlin et al., 2003). In addition, SHP blocks PXR interac-
tion withHNF4α but does not affect PXR and PGC-1α interaction
(Li and Chiang, 2006). In addition SHP blocks PXR binding to
CYP3A4 promoterDNA (Ourlin et al., 2003; Li andChiang, 2006).
In a positive feedback loop, PXR was supposed to inhibit SHP
gene transactivation and SHP mRNA expression to maximize the
PXR induction of the CYP3A4 gene in human hepatocytes (Li and
Chiang, 2006).
The aim of this study was to examine in detail the effect of
rifampicin on SHP expression in PXR-mediated transactivation of
the main drug-metabolizing enzyme, CYP3A4, in primary human
hepatocytes. In particular, we examined the effect of a proto-
type PXR ligand rifampicin on SHP protein expression in several
primary human hepatocyte preparations.
MATERIALS AND METHODS
CELL LINES AND PRIMARY HUMAN HEPATOCYTES
The human MZ-Hep1 hepatocarcinoma cell line (kindly donated
by Dr. Ramiro Jover, Hospital La Fe, Valencia, Spain) was main-
tained in antibiotic-free DMEM supplemented with 10% Fetal
bovine serum (FBS) and 1mM sodium pyruvate. FBS was pur-
chased from PAA (Pasching, Austria). Other chemicals and cell
culturemedia were purchased from Sigma-Aldrich (St. Louis,MO,
USA). The ﬁnal concentration of DMSO in the culture media was
0.1% (v/v) in all experiments.
Long-term human hepatocytes in monolayer were purchased
from Biopredic International, Rennes, France, and were main-
tained according to the protocols provided by Biopredic. The
mediumwas exchanged for serum-freemedium theday after deliv-
ery,and the culturewas allowed to stabilize for an additional 6–24 h
prior to treatments.
LH28 and LH29 primary human hepatocyte preparations were
isolated, cultivated, and treated as described in our previous papers
(Bachleda et al., 2009; Dvorak et al., 2010). Our tissue prepara-
tion protocol was designed in accordance with the requirements
issued by local ethical commissions in theCzechRepublic. In addi-
tion, we used three commercial preparations of Long-term human
hepatocytes in monolayer : Batch HEP220466 (75-year-old female
suffering from hepatocellular carcinoma), Batch HEP220465 (63-
year-old male with liver metastases), and Batch HEP220492 (66-
year-old female with hepatic metastases; Biopredic International,
Rennes, France).
DNA CONSTRUCTS
A chimeric p3A4–luc reporter construct containing the basal pro-
moter (−362/+53) and the distal xenobiotic responsive enhancer
module (−7836/−7208) of the CYP3A4 gene 5′-ﬂanking region
was described elsewhere (Cerveny et al., 2007). The expression
plasmids for PXR and SHP receptors, pSG5–hPXR, and pSG5–
hSHP, were kindly provided by Dr. S. Kliewer (University of Texas,
TX, USA). pRL–TK was purchased from Promega and the empty
pSG5 vector was purchased from Stratagene.
TRANSIENT TRANSFECTION AND LUCIFERASE GENE REPORTER
ASSAYS
All transient transfection assayswere carried out inMZ-Hep1 cells,
as described previously (Pavek et al., 2010).
QUANTITATIVE REAL-TIME RT-PCR
Total RNA isolation and quantitative real-time RT-PCR
(qRT-PCR) analyses of CYP3A4 (hCYP3A4_Q2) and SHP
(hNR0B2_Q2) mRNA expression in primary human hepatocytes
were performed by employing commercial assays from Generi-
Biotech (Hradec Kralove, Czech Republic) as described elsewhere
(Pavek et al., 2007, 2010; Svecova et al., 2008). HPRT (hHPRT_Q3)
housekeeping gene expression levels were used as normalization
controls. Experiments were performed in triplicates (i.e., three
individual cell samples) and each cDNA sample has been analyzed
as triplicate in one RT-PCR run.
IMMUNOBLOTTING
The relative abundance of each speciﬁc protein in 25–50μg of
whole cell lysate was determined by Western blot analysis, as
described previously (Pospechova et al., 2009). Anti-SHP (H-160:
sc-30169; dilution 1:250), anti-human CYP3A4 (HL3: sc53850;
1:2000), and goat polyclonal anti-actin antibodies (clone I-19:
1616; a loading control) were purchased from Santa Cruz Biotech-
nology, Inc. (Santa Cruz, USA). Densitometric analyses have been
performed to semi-quantify the expression of the tested proteins.
STATISTICAL ANALYSES
All data are expressed as the mean± SD. Differences between the
groups were compared with Student’s paired two-tailed t -test.
Kruskal–Wallis testwithDunn’sMultipleComparison post hoc test
andOne-way analysis of variance (ANOVA) with Tukey’sMultiple
Comparison test were use to analyze data in Figure 3. All statisti-
cal analyses were performed using GraphPad Prism 4 Software. p
Value<0.05 was considered statistically signiﬁcant.
RESULTS
RIFAMPICIN DOES NOT SYSTEMATICALLY SUPPRESS SHP mRNA GENE
EXPRESSION IN PRIMARY HUMAN HEPATOCYTES
First, we examined whether rifampicin, a prototype PXR ligand,
affects the expression of SHP mRNA in primary human hepa-
tocytes. We found that rifampicin (10μM) had no statistically
signiﬁcant effect on SHP mRNA expression on three primary
human hepatocyte cultures (analyzed with Student’s paired t -test,
Figure 1A), although in individual preparations we observed the
effect of rifampicin on SHP mRNA expression. At the same time,
we evaluated the expression of themain PXR target gene,CYP3A4.
We found that rifampicin (10μM)signiﬁcantly (p< 0.01) induced
expression of CYP3A4 mRNA after 24 h in the same primary
human hepatocyte preparations (analyzed with Student’s paired
t -test, Figure 1B). The effect of rifampicin on CYP3A4 mRNA
expression reﬂects high inter-individual variation in response to
PXR inducers in various hepatocyte preparations and in human
population.
RIFAMPICIN DOES NOT SYSTEMATICALLY AFFECT SHP PROTEIN
EXPRESSION IN PRIMARY HUMAN HEPATOCYTES
In next experiments,we examined the effect of rifampicin (10μM)
on SHP protein expression in hepatocytes treated with rifampicin
employing Western blotting analysis. Rifampicin did not signiﬁ-
cantly decrease SHP protein expression after 24 or 48 h treatment
in either human hepatocyte preparation (Figures 2A,B).
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FIGURE 1 | Pregnane X receptor activation with rifampicin (10μM) has
variable effects on SHP mRNA expression in primary human
hepatocytes. Primary human hepatocyte cultures (HEP220466, LH28,
HEP220492) were treated with rifampicin (Rif, 10μM) for 24 h. Total RNA
was isolated, and mRNA levels were analyzed by qRT-PCR. The effects of
rifampicin (10μM) on the mRNA levels of SHP (A,B) CYP3A4 genes were
normalized to housekeeping HPRT mRNA and are presented as the relative
mRNA expression compared to control vehicle (DMSO)-treated cells
(set to 1).
THE EFFECTS OF SHP OVEREXPRESSION ON CYP3A4
TRANSACTIVATION IN GENE REPORTER ASSAYS
In next transient transfection gene reporter experiments with
p3A4–luc construct, we examined whether SHP suppresses
CYP3A4 in gene reporter assays in hepatocellular carcinoma cell
line MZ-Hep1 cells. The MZ-Hep1 cell line was conﬁrmed to
expresses SHP protein (Figure 2B). Consistently with reported
data in other liver-derived cell lines (Ourlin et al., 2003; Li and
Chiang, 2006), we observed that overexpression of SHP signiﬁ-
cantly abolished rifampicin-mediated activation of the CYP3A4
construct (p< 0.01, ANOVA) with Tukey’s Multiple Comparison
test; Figure 3).
DISCUSSION
Recently, Li and Chiang proposed an elegant model of PXR-
mediated transactivation of CYP3A4 in human hepatocytes
(Li and Chiang, 2006). This model supposes that activated PXR
FIGURE 2 | Pregnane X receptor activation with rifampicin (10μM) has
no effect on SHP protein expression in primary human hepatocytes.
Primary human hepatocyte cultures were treated with rifampicin (Rif,
10μM) for 24 (A) or 48 h (B). SHP protein levels were analyzed byWestern
blotting with speciﬁc antibody.
FIGURE 3 | Small/short heterodimer partner overexpression abolishes
CYP3A4 transactivation in gene reporter assay in MZ-Hep1 cells.
MZ-Hep1 cells were cotransfected with p3A4–luc reporter construct (200 ng
per well in 48-well plate), expression constructs for PXR (50 ng per well), or
expression construct for SHP (50 ng, or appropriate amount of pSG5 empty
vector). After 24 h incubation with rifampicin (10μM), triplicates of cell
samples were lysed and analyzed for ﬁreﬂy normalized to Renilla luciferase
activity. Data represent the mean of three independent experiments and
are shown as fold activation of normalized luciferase activity relative to
solvent (0.1% DMSO) controls (set to 1). Statistically signiﬁcant to vehicle
(DMSO)-treated cells cotransfected under the same experimental
conditions ∗∗∗p<0.01; statistically signiﬁcant to rifampicin-treated cells
cotransfected under the same experimental conditions
∫∫∫
p<0.01
(Kruskal–Wallis test with Dunn’s Multiple Comparison post hoc test and
ANOVA with Tukey’s Multiple Comparison test). SHP protein levels in
MZ-Hep1 cells were analyzed byWestern blotting with speciﬁc antibody.
trans-represses SHP expression and since SHP competes with
HNF4α and SRC1 coactivators for binding to PXR, this feed-
back loop maximizes PXR-mediated induction of the CYP3A4
gene.
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Nevertheless, earlier reports did not ﬁnd any statistically signif-
icant effects of PXR and rodent ortholog Pxr activation, either by
speciﬁc ligands or using engineered animalmodels, on SHP or Shp
transcript expression (Ourlin et al., 2003; Rosenfeld et al., 2003;
Hartley et al., 2004; Guzelian et al., 2006; Bailey et al., 2011) or on
SHP binding to PXR target genes promoters employing chromatin
immunoprecipitation (ChIP; Hariparsad et al., 2009). In primary
human hepatocytes, Ourlin et al. (2003) ﬁrst reported no effect of
rifampicin on SHP mRNA expression.
In our experiments, we did not observe signiﬁcant effect
of rifampicin on SHP expression, although slight decrease was
observed in some experiments. Notably, we observed hepato-
cyte preparation-dependent effect of rifampicin on SHP mRNA
expression (Figure 1A). These datamight indicate inter-individual
effect of PXR activation on SHP expression in hepatocytes.We can
also consider some unspeciﬁed dietary, physiological, or environ-
mental aspects of inter-individual response to PXR activation in
terms of SHP expression.
Indeed, in population, CYP3A4 displays high inter-individual
variability in expression and catalytic activity in the liver. To date,
however,no single nucleotide polymorphisms of theCYP3A4 gene
coding region or its promoter region have been found as the
direct cause of the variability (Martinez-Jimenez et al., 2007). It
is therefore supposed that transcription activity of nuclear recep-
tors including SHP might be the cause of CYP3A4 expression
variability in the liver and in the intestine.
We conclude that the physiological role of SHP in regulation of
CYP3A4 induction needs to be further studied in a larger popula-
tion of human hepatocyte preparations. In addition, our results
again conﬁrm that SHP is an important negative regulator of
CYP3A4 transactivation that may contribute to inter-individual
variability in CYP3A4 hepatic expression.
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